A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.Peer-Reviewed Original ResearchPlasma cell disorderStandard armInfluenza vaccineMyeloma patientsIntensive armDaratumumab exposureRandomized controlled trialsMultiple myelomaFlu seasonCell disordersHistory of severe allergic reactionsStandard-dose influenza vaccinesTreat analysisRisk of influenza-like illnessT-cell engagersSeasonal influenza vaccineHigh dose vaccineHigh dose injectionsInfluenza-like illnessProportion of patientsFlu vaccinationVaccine preventable illnessYears of ageSevere allergic reactionsStatistically significant differenceSingle Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers
Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.Peer-Reviewed Original ResearchB-cell maturation antigenRefractory myelomaAnti-BCMABispecific antibodiesInternational Myeloma Working Group Uniform Response CriteriaInstitutional experienceWinship Cancer Institute of Emory UniversityCAR-T cell therapyBispecific T-cell engagerSignificant tumor burdenT-cell engagersDecreased performance statusWinship Cancer InstituteRate of gradeLimited treatment optionsStatistically significant differenceMedian PFSPretreated patientsCAR-TMedian followResponse CriteriaTumor burdenPretreated populationDose reductionMaturation antigen